From: Correlation between CpG methylation profiles and hormone receptor status in breast cancers
Clinicopathologic factors | Number of sample |
---|---|
Age | 90 |
Median, range | 57 years, 29–81 years |
Tumor grade (BNG) | 89 |
1 | 3 |
2 | 47 |
3 | 39 |
Tumor size | 90 |
T1 | 19 |
T2 | 36 |
T3 | 18 |
T4 | 17 |
Stage | 90 |
I | 15 |
II | 37 |
III | 38 |
Lymph-node metastasis | 90 |
pN0 | 39 |
pN1 | 28 |
pN2 | 9 |
pN3 | 14 |
Lymphatic invasion | 78 |
Positive | 33 |
Negative | 45 |
Vascular invasion | 78 |
Positive | 32 |
Negative | 46 |
ER status | 87 |
Positive | 52 |
Negative | 35 |
PR status | 87 |
Positive | 40 |
Negative | 47 |
Hormone receptor status | 87 |
Positive (ER- and/or PR-positive) | 55 |
Negative (both ER- and PR-negative) | 32 |
HER-2/neu status | 80 |
Positive | 7 |
Negative | 73 |
Histology | 90 |
Ductal | 62 |
Lobular | 8 |
Mixed ductal and lobular | 9 |
Other | 11 |